therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-81563033-8344РостГМУ10.21886/2712-8156-2022-3-1-20-25therapeutic-215Research ArticleОБЗОРЫREVIEWSГепаторенальный синдром: критерии и проблемы диагностики (часть II)Hepatorenal syndrome: criteria and problems of diagnosis (part II)https://orcid.org/0000-0002-5754-4418КрутиковЕ. С.KrutikovE. S.

Крутиков Евгений Сергеевич – доктор медицинских наук, профессор, заведующий кафедрой пропедевтики внутренней медицины.

Симферополь.

Evgeniy S. Krutikov - Dr. Sci. (Med.), Professor, head Department of Propedeutics of Internal Medicine, S.I. Georgievsky Medical Academy of Vernadsky Crimean Federal University.

Simferopol.

nephrostar@yandex.ruhttps://orcid.org/0000-0002-5100-1535ВостриковаА. Н.VostrikovaA. N.

Вострикова Александра Николаевна - студент кафедры внутренней медицины №1.

Симферополь.

Aleksandra N. Vostrikova - student, Chair of Internal Medicine No. 1, S.I. Georgievsky Medical Academy of Vernadsky Crimean Federal University.

Simferopol.

ip4ne@mail.ruhttps://orcid.org/0000-0001-6200-8524КрутиковаМ. С.KrutikovaM. S.

Крутикова Марина Сергеевна – кандидат медицинских наук, доцент кафедры внутренней медицины.

Симферополь.

Marina S. Krutikova - Cand. Sci. (Med.), Associate Professor, Chair of Internal Medicine No. 1 S.I. Georgievsky Medical Academy of Vernadsky Crimean Federal University.

Simferopol.

marina_ua_22@mail.ruМедицинская академия имени С.И. Георгиевского ФГАОУ ВО «Крымский федеральный университет им. В.И. Вернадского»РоссияS.I. Georgievsky Medical Academy of Vernadsky Crimean Federal UniversityRussian Federation202216032022312025Copyright © Крутиков Е.С., Вострикова А.Н., Крутикова М.С., 20222022Крутиков Е.С., Вострикова А.Н., Крутикова М.С.Krutikov E.S., Vostrikova A.N., Krutikova M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/215

Гепаторенальный синдром — развитие почечной недостаточности у больных циррозом печени характеризуется снижением почечного кровотока и скорости клубочковой фильтрации. Гепаторенальный синдром диагностируется, когда функция почек снижена, но отсутствуют признаки хронического заболевания почек. В отличие от других причин повреждения почек гепаторенальный синдром возникает в результате функциональных изменений в почечной циркуляции и потенциально обратим. Проведен анализ обзоров литературы, клинических исследований, экспериментальных исследований, клинических рекомендаций из баз данных PubMed / MedLine и eLIBRARY, по семи ключевым словам, соответствующим теме обзора.

Hepatorenal syndrome, the extreme manifestation of renal impairment in patients with cirrhosis, is characterized by reduction in renal blood flow and glomerular filtration rate. Hepatorenal syndrome is diagnosed when kidney function is reduced but evidence of intrinsic kidney disease is absent. Unlike other causes of kidney injury, hepatorenal syndrome results from functional changes in the renal circulation and is potentially reversible. An analysis of literature reviews, clinical studies, experimental research, clinical recommendations from PubMed / Medline and ELIBRARY databases was carried out for 7 keywords according to the review topic.

цирроз печенигепаторенальный синдромдиагностикаобзор литературыliver cirrhosishepatorenal syndromediagnosistreatmentliterature reviewReferencesScarpellini E., Luigiano C., Svegliati-Baroni G., Dumitrascu D., Larussa T., Santori V., et al. Liver Cirrhosis Complications M anagement at the Emergency Department. Rev Recent. Clin Trials. 2020;15(4):331-338. DOI: 10.2174/1574887115666200603160816Scarpellini E., Luigiano C., Svegliati-Baroni G., Dumitrascu D., Larussa T., Santori V., et al. Liver Cirrhosis Complications M anagement at the Emergency Department. Rev Recent. Clin Trials. 2020;15(4):331-338. DOI: 10.2174/1574887115666200603160816EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. DOI: 10.1016/j.jhep.2018.03.024EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. DOI: 10.1016/j.jhep.2018.03.024Angeli P., Garcia-Tsao G., Nadim M.K., Parikh C.R. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71(4):811-822. DOI: 10.1016/j.jhep.2019.07.002Angeli P., Garcia-Tsao G., Nadim M.K., Parikh C.R. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71(4):811-822. DOI: 10.1016/j.jhep.2019.07.002Simonetto D. A., Gines P., Kamath P.S. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687. DOI: 10.1136/bmj.m2687Simonetto D. A., Gines P., Kamath P.S. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687. DOI: 10.1136/bmj.m2687Alessandria C., Ozdogan O., Guevara M., RestucciaT., Jimenez W., Arroyo V., et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. Hepatology. 2005;41:1282-1289. DOI: 10.1002/hep.20687.Alessandria C., Ozdogan O., Guevara M., RestucciaT., Jimenez W., Arroyo V., et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. Hepatology. 2005;41:1282-1289. DOI: 10.1002/hep.20687.Bucsics T., Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017;5(2):127-137. DOI: 10.1093/gastro/gox009Bucsics T., Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017;5(2):127-137. DOI: 10.1093/gastro/gox009Tujios S.R., Hynan L.S., Vazquez M.A., Larson A.M., Seremba E., Sanders C.M., et al. Acute Liver Failure Study Group. Risk factors and outcomes of acute kidney injury in patients with acute liver failure. Clin Gastroenterol Hepatol. 2015;13:352-359. DOI: 10.1016/j.cgh.2014.07.011.Tujios S.R., Hynan L.S., Vazquez M.A., Larson A.M., Seremba E., Sanders C.M., et al. Acute Liver Failure Study Group. Risk factors and outcomes of acute kidney injury in patients with acute liver failure. Clin Gastroenterol Hepatol. 2015;13:352-359. DOI: 10.1016/j.cgh.2014.07.011.Mindikoglu A. L. New Developments in hepatorenal syndrome. Clin Gastroenterol. Hepatol. 2018; 16(2): 162-177. DOI: 10.1016/j.cgh.2017.05.041Mindikoglu A. L. New Developments in hepatorenal syndrome. Clin Gastroenterol. Hepatol. 2018; 16(2): 162-177. DOI: 10.1016/j.cgh.2017.05.041Trawa^ J.M., Paradis V., Rautou P.E., Francoz C., Escolano S., Sal^e M., et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int. 2010;30:725-732. DOI: 10.1111/j.1478-3231.2009.02182.xTrawa^ J.M., Paradis V., Rautou P.E., Francoz C., Escolano S., Sal^e M., et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int. 2010;30:725-732. DOI: 10.1111/j.1478-3231.2009.02182.xSherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis. 2003;41:269-278. DOI: 10.1053/ajkd.2003.50035Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis. 2003;41:269-278. DOI: 10.1053/ajkd.2003.50035Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010;52:605-613. DOI: 10.1016/j.jhep.2009.11.025Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010;52:605-613. DOI: 10.1016/j.jhep.2009.11.025Cocchetto DM, Tschanz C, Bjornsson TD. Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit. 1983;5:161-168. DOI: 10.1097/00007691-19830600000002Cocchetto DM, Tschanz C, Bjornsson TD. Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit. 1983;5:161-168. DOI: 10.1097/00007691-19830600000002Francoz C., Prie D., Abdelrazek W. Moreau R., Mandot A., Belghiti J., et al. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transplant. 2010;16:1169-77. DOI: 10.1002/lt.22128Francoz C., Prie D., Abdelrazek W. Moreau R., Mandot A., Belghiti J., et al. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transplant. 2010;16:1169-77. DOI: 10.1002/lt.22128Nadim M.K., Kellum J.A., Davenport A., Wong F., Davis C., Pannu N., et al. Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2012;16:R23. DOI: 10.1186/cc11188Nadim M.K., Kellum J.A., Davenport A., Wong F., Davis C., Pannu N., et al. Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2012;16:R23. DOI: 10.1186/cc11188Stevens L.A., Coresh J., Greene T., Levey A.S. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006; 354:2473-2483. DOI: 10.1056/NEJMra054415Stevens L.A., Coresh J., Greene T., Levey A.S. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006; 354:2473-2483. DOI: 10.1056/NEJMra054415Cholongitas E, Shusang V, Marelli L., Nair D., Thomas M., Patch D., et al. Review article: renal function assessment in cirrhosis— difficulties and alternative measurements. Aliment Pharmacol Ther. 2007;26:969-978. DOI: 10.1111/j.1365-2036.2007.03443.xCholongitas E, Shusang V, Marelli L., Nair D., Thomas M., Patch D., et al. Review article: renal function assessment in cirrhosis— difficulties and alternative measurements. Aliment Pharmacol Ther. 2007;26:969-978. DOI: 10.1111/j.1365-2036.2007.03443.xKrones E., Fickert P., Zitta S. Neunherz S.,Artinger K.,Reibnegger G. et al. The chronic kidney disease epidemiology collaboration equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis. BMC Nephrol. 2015;16:1-10. DOI: 10.1186/s12882-015-0188-0Krones E., Fickert P., Zitta S. Neunherz S.,Artinger K.,Reibnegger G. et al. The chronic kidney disease epidemiology collaboration equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis. BMC Nephrol. 2015;16:1-10. DOI: 10.1186/s12882-015-0188-0Mindikoglu A.L., Dowling T.C., Weir M.R., Seliger S.L., Christenson R.H., Magder L.S. Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology. 2014;59:1532-1542. DOI: 10.1002/hep.26556Mindikoglu A.L., Dowling T.C., Weir M.R., Seliger S.L., Christenson R.H., Magder L.S. Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology. 2014;59:1532-1542. DOI: 10.1002/hep.26556Arroyo V. A new method for therapeutic paracentesis: The automated low flow pump system. Comments in the context of the history of paracentesis. J Hepathology. 2013;58(5):850-852. DOI: 10.1016/j.jhep.2013.01.037Arroyo V. A new method for therapeutic paracentesis: The automated low flow pump system. Comments in the context of the history of paracentesis. J Hepathology. 2013;58(5):850-852. DOI: 10.1016/j.jhep.2013.01.037Stevens L.A., Schmid C.H., Greene T. Li L., Beck G.J., Joffe M.M., et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75:652-60. DOI: 10.1038/ki.2008.638Stevens L.A., Schmid C.H., Greene T. Li L., Beck G.J., Joffe M.M., et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75:652-60. DOI: 10.1038/ki.2008.638Al-Hazmi SF., Gad H.G.M., Alamoudi A.A., Eldakhakhny B.M., Binmahfooz S.K., Alhozali A.M. Evaluation of early biomarkers of renal dysfunction in diabetic patients. Saudi Med J. 2020;41(7):690-697. DOI: 10.15537/smj.2020.7.25168.Al-Hazmi SF., Gad H.G.M., Alamoudi A.A., Eldakhakhny B.M., Binmahfooz S.K., Alhozali A.M. Evaluation of early biomarkers of renal dysfunction in diabetic patients. Saudi Med J. 2020;41(7):690-697. DOI: 10.15537/smj.2020.7.25168.Rao X., Wan M., Qiu C., Jiang C. Role of cystatin C in renal damage and the optimum cut-off point of renal damage among patients with type 2 diabetes mellitus. Experimental and therapeutic medicine. 2014; 8(3): 887-892. DOI: 10.3892/etm.2014.1815Rao X., Wan M., Qiu C., Jiang C. Role of cystatin C in renal damage and the optimum cut-off point of renal damage among patients with type 2 diabetes mellitus. Experimental and therapeutic medicine. 2014; 8(3): 887-892. DOI: 10.3892/etm.2014.1815Singal Russ K.B., Stevens T.M., Singal A.K. Acute Kidney Injury in Patients with Cirrhosis. J Clin Transl Hepatol. 2015;3(3):195-04. DOI: 10.14218/JCTH.2015.00015Singal Russ K.B., Stevens T.M., Singal A.K. Acute Kidney Injury in Patients with Cirrhosis. J Clin Transl Hepatol. 2015;3(3):195-04. DOI: 10.14218/JCTH.2015.00015Martm-LlafuM, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology. 2011;140(2):488. DOI: 10.1053/j.gastro.2010.07.043Martm-LlafuM, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology. 2011;140(2):488. DOI: 10.1053/j.gastro.2010.07.043Mandorfer M., Bota S., Schwabl P., Bucsics T., Pfisterer N., Kruzik M., et al. Nonselective в blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146:1680-90.el. DOI: 10.1053/j.gastro.2014.03.005Mandorfer M., Bota S., Schwabl P., Bucsics T., Pfisterer N., Kruzik M., et al. Nonselective в blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146:1680-90.el. DOI: 10.1053/j.gastro.2014.03.005Boyer T.D., Sanyal A.J., Wong F., Frederick R.T., Lake J.R., O'Leary J.G., et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150:1579-1589. DOI: 10.1053/j.gastro.2016.02.026Boyer T.D., Sanyal A.J., Wong F., Frederick R.T., Lake J.R., O'Leary J.G., et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150:1579-1589. DOI: 10.1053/j.gastro.2016.02.026Cavallin M., Kamath P.S., Merli M., Fasolato S., Toniutto P., Salerno F., et al. Terlipressin plus albumin vs. midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62:567-574. DOI: 10.1002/hep.27709Cavallin M., Kamath P.S., Merli M., Fasolato S., Toniutto P., Salerno F., et al. Terlipressin plus albumin vs. midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62:567-574. DOI: 10.1002/hep.27709Cavallin M., Piano S., Romano A., Fasolato S., Frigo A.C., Benetti G., et al. Terlipressin given by continuous intravenous infusion vs. intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology. 2016;63:983-992. DOI: 10.1002/hep.28396Cavallin M., Piano S., Romano A., Fasolato S., Frigo A.C., Benetti G., et al. Terlipressin given by continuous intravenous infusion vs. intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology. 2016;63:983-992. DOI: 10.1002/hep.28396Piano S., Schmidt H.H., Ariza X., Amoros A., Romano A., Sola E., et al. Impact of Acute-on-Chronic Liver Failure on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome. Digestive and Liver Disease. 2017;49(1): e54. DOI: 10.1016/j.dld.2017.01.108Piano S., Schmidt H.H., Ariza X., Amoros A., Romano A., Sola E., et al. Impact of Acute-on-Chronic Liver Failure on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome. Digestive and Liver Disease. 2017;49(1): e54. DOI: 10.1016/j.dld.2017.01.108Глумчер Ф.С. Возможности применения альбумина в терапии критических состояний: современное состояние проблемы. Медицина неотложных состояний. 2014;2(57):65-73.Глумчер Ф.С. Возможности применения альбумина в терапии критических состояний: современное состояние проблемы. Медицина неотложных состояний. 2014;2(57):65-73.Смирнов А.В., Румянцев А.Ш.* от имени рабочей группы. Острое повреждение почек. Часть I. Нефрология. 2020;24(1):67- 95. DOI: 10.36485/1561-6274-2020-24-1-67-95Смирнов А.В., Румянцев А.Ш.* от имени рабочей группы. Острое повреждение почек. Часть I. Нефрология. 2020;24(1):67- 95. DOI: 10.36485/1561-6274-2020-24-1-67-95Angeli P., Gines P., Wong F., Bernardi M., Boyer T.D., Gerbes A., et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968-974. DOI: 10.1016/j.jhep.2014.12.029Angeli P., Gines P., Wong F., Bernardi M., Boyer T.D., Gerbes A., et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968-974. DOI: 10.1016/j.jhep.2014.12.029Nadim M.K., Durand F., Kellum J.A. Levitsky J., O'Leary J.G., Karvellas C.J., et al. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. J Hepatol. 2016; 64:717-735. DOI: 10.1016/j.jhep.2015.10.019Nadim M.K., Durand F., Kellum J.A. Levitsky J., O'Leary J.G., Karvellas C.J., et al. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. J Hepatol. 2016; 64:717-735. DOI: 10.1016/j.jhep.2015.10.019O'Leary J.G., Levitsky J., Wong F., Nadim M. K., Charlton M., Kim W. R. Protecting the kidney in liver transplant candidates Practice Based Recommendations from the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant. 2016;16(9):2516-2531. DOI: 10.1111/ajt.13790O'Leary J.G., Levitsky J., Wong F., Nadim M. K., Charlton M., Kim W. R. Protecting the kidney in liver transplant candidates Practice Based Recommendations from the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant. 2016;16(9):2516-2531. DOI: 10.1111/ajt.1379035. Mindikoglu A.L., Dowling T.C., Wong-You-Cheong J.J., Christenson R.H., Magder L. S., Hutson W. R., et al. A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol. 2014; 39:543-552. DOI: 10.1159/000363584Mindikoglu A.L., Dowling T.C., Wong-You-Cheong J.J., Christenson R.H., Magder L. S., Hutson W. R., et al. A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol. 2014; 39:543-552. DOI: 10.1159/000363584Rivolta R., Maggi A., Cazzaniga M., Castagnone D.,Panzeri A., Solenghi D., et al. Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites. Hepatology. 1998; 28:1235-1240. DOI: 10.1002/hep.510280510Rivolta R., Maggi A., Cazzaniga M., Castagnone D.,Panzeri A., Solenghi D., et al. Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites. Hepatology. 1998; 28:1235-1240. DOI: 10.1002/hep.510280510Mindikoglu A.L., Weir M.R. Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol. 2013; 38:345-354. DOI: 10.1159/000355540Mindikoglu A.L., Weir M.R. Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol. 2013; 38:345-354. DOI: 10.1159/000355540Fagundes C., Pepin M.N., Guevara M., Barreto R., Casals G., Sola E., et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol. 2012; 57:267-273. DOI: 10.1016/j.jhep.2012.03.015Fagundes C., Pepin M.N., Guevara M., Barreto R., Casals G., Sola E., et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol. 2012; 57:267-273. DOI: 10.1016/j.jhep.2012.03.015Belcher J.M., Sanyal A.J., Peixoto A.J., Perazella M.A., Lim J., Thiessen-Philbrook H., et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014; 60:622-632. DOI: 10.1002/hep.26980Belcher J.M., Sanyal A.J., Peixoto A.J., Perazella M.A., Lim J., Thiessen-Philbrook H., et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014; 60:622-632. DOI: 10.1002/hep.26980Лихота О.С., Цикуниб А.Д. Особенности метаболизма и маркеры биохимических нарушений в печени при гепатитах. Наука: комплексные проблемы. - 2017;1(9):4-11.Лихота О.С., Цикуниб А.Д. Особенности метаболизма и маркеры биохимических нарушений в печени при гепатитах. Наука: комплексные проблемы. - 2017;1(9):4-11.41. Саварина В.А., Мицура В.М., Скуратов А.Г., Мартемьянова Л.А. Проблемы диагностики гепаторенального синдрома в практике клинициста и патологоанатома. Проблемы Здоровья и Экологии. 2020;65(3):49-55.Саварина В.А., Мицура В.М., Скуратов А.Г., Мартемьянова Л.А. Проблемы диагностики гепаторенального синдрома в практике клинициста и патологоанатома. Проблемы Здоровья и Экологии. 2020;65(3):49-55.Сливка Н.А., Вирстюк Н.Г., Давыденко И.С., Мартынюк Г.А., Бевз Т.И., Гайдуков В.А. Гистологические изменения почек при гепаторенальном синдроме на фоне алкогольного цирроза печени. Клиническая и экспериментальная патология. 2018;4(66):71-75. DOI: 10.24061/1727-4338.XVII.4.66.2018.191Сливка Н.А., Вирстюк Н.Г., Давыденко И.С., Мартынюк Г.А., Бевз Т.И., Гайдуков В.А. Гистологические изменения почек при гепаторенальном синдроме на фоне алкогольного цирроза печени. Клиническая и экспериментальная патология. 2018;4(66):71-75. DOI: 10.24061/1727-4338.XVII.4.66.2018.191Вирстюк Н.Г., Сливка Н.А. Диагностическая ценность допплерографического исследования при гепаторенальном синдроме. Гастроэнтерология. 2017;1(51):8-15. DOI: 10.22141/2308-2097.51.1.2017.97866Вирстюк Н.Г., Сливка Н.А. Диагностическая ценность допплерографического исследования при гепаторенальном синдроме. Гастроэнтерология. 2017;1(51):8-15. DOI: 10.22141/2308-2097.51.1.2017.97866

The authors declare that there are no conflicts of interest present.